CRANBURY, NJ (TheStreet) -- Amicus Therapeutics CEO John Crowley came close to permanentlyashelving his company's experimental Fabry disease therapyafollowing disappointing results from a late-stageastudy in December 2012 and the departure of partner GlaxoSmithKline about one year later. But Crowley -- famous for his perseverance -- decided to stick with the drug, migalastat, in the hope that a slower-to-enroll, second phase III study would resurrect chances for eventual approval.